Apollomics (APLM) vs RenovoRx (RNXT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Apollomics (APLM) has outperformed RenovoRx (RNXT) over the past year, gaining 16.6% versus a gain of 12.3%. Apollomics is the larger company by market cap ($62.7 million vs $61.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APLM | RNXT |
|---|---|---|
| Share price | $21.50 | $1.37 |
| Market cap | $62.67M | $61.83M |
| 1-day change | -2.71% | -1.44% |
| YTD return | +15.00% | +63.10% |
| 1-year return | +16.64% | +12.30% |
| 5-year return | — | -77.09% |
| EPS (TTM) | $-7.57 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $42.12 | $2.59 |
| 52-week low | $10.01 | $0.701 |
| Distance from 52-week high | -48.96% | -47.10% |
| Average volume | 21.85K | 753.57K |
| Shares outstanding | 2.91M | 45.13M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
APLM vs RNXT FAQ
Which is bigger, Apollomics or RenovoRx?
Apollomics (APLM) is larger, with a market capitalization of $62.67M compared with $61.83M for RenovoRx (RNXT).
Which stock has performed better over the past year, APLM or RNXT?
APLM returned +16.64% over the past 12 months, compared with +12.30% for RNXT (price return, excluding dividends). Past performance does not predict future results.
Are Apollomics and RenovoRx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.